<DOC>
	<DOC>NCT02232529</DOC>
	<brief_summary>The aim of the study is to assess how MIN-101 is taken up by the body when given in different amounts and in different formulations. The drug will be given as a single dose in Part 1 of the study and during Part 2 of the study as multiple dose, once daily for 7 days. The ultimate aim is to find an optimal formulation which can be developed as a once daily dose for the treatment of schizophrenia.</brief_summary>
	<brief_title>Pharmacokinetic Study of MIN-101 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy males (Part 1 and Part 2) or nonpregnant, nonlactating healthy females (Part 2 only) Body mass index (BMI) of 18.0 to 30.0 kg/m2 Must be CYP2D6 Extensive metabolizer Must be willing and able to communicate and participate in the whole study Must provide written informed consent Must agree to use an adequate method of contraception Key Subjects who have QTc &gt; 430 in male, &gt; 450 in female confirmed by a repeat ECG Any family history of sudden cardiac death and Torsade de Points No personal or family history of unexplained presyncope, syncope or orthostatic hypotension History of any drug or alcohol abuse in the past 2 years History or evidence of any medically diagnosed clinically significant psychiatric disorders Suicidal tendencies or history of suicidal attempts Regular alcohol consumption in males &gt;21 units per week and females &gt;14 units per week (1 unit = Â½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening Females of childbearing potential who are pregnant or lactating (female subjects must have a negative urine pregnancy test at admission) Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator Positive drugs of abuse test result Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>modified release formulation</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>